Drugs / Ringer's Lactate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01108601 | Apr 2008 → Apr 2011 | hearing loss disorder | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04152096 | Feb 2017 → Sep 2020 | poisoning | Yuria-Pharm | Completed | No outcome recorded |
| Phase 4 | NCT00273728 | May 2005 → Jun 2010 | infectious disease with sepsis | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Comparator or background therapy31 trials | ||||||
| Phase 1 | NCT06622499 Comparator | Nov → Dec 2023 | — | Esbjerg Hospital - University Hospital of Southern Denmark | Completed | No outcome recorded |
| Phase 1/2 | NCT00494949 Comparator | Apr 2003 → Jul 2006 | hypotensive disorder | Sangart | Completed | No outcome recorded |
| Phase 2 | NCT02726308 Comparator | May 2015 → Mar 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT00425334 Comparator | Jul 2005 → Oct 2007 | prostate cancer | Sangart | Completed | No outcome recorded |
| Phase 2/3 | NCT06461390 Comparator | Mar → May 2024 | infectious disease with sepsis | Indonesia University | Completed | No outcome recorded |
| Phase 2/3 | NCT05658406 Comparator | Jan → Jul 2022 | — | Alexandria University | Completed | No outcome recorded |
| Phase 3 | NCT04076254 Comparator | Oct 2016 → Sep 2019 | Dengue hemorrhagic fever | Indonesia University | Unknown | No outcome recorded |
| Phase 3 | NCT01433276 Comparator | Jul 2009 → Jan 2011 | — | Innogene Kalbiotech Pte. Ltd | Completed | No outcome recorded |
| Phase 3 | NCT00966628 Comparator | May 2008 → Apr 2009 | dengue shock syndrome | Innogene Kalbiotech Pte. Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT00529711 Comparator | Jul 2005 → Jul 2006 | cardiogenic shock | Innogene Kalbiotech Pte. Ltd | Completed | No outcome recorded |
| Phase 3 | NCT00529490 Comparator | Mar 2002 → Jun 2003 | — | Innogene Kalbiotech Pte. Ltd | Completed | No outcome recorded |
| Phase 4 | NCT05610254 Comparator | Oct → Dec 2022 | — | Esbjerg Hospital - University Hospital of Southern Denmark | Completed | No outcome recorded |
| Phase 4 | NCT03764085 Comparator | Dec 2016 → Dec 2019 | infectious disease with sepsis | Yuria-Pharm | Completed | No outcome recorded |
| Phase 4 | NCT04512950 Comparator | Aug 2016 → Jun 2020 | — | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01692769 Comparator | May 2013 → Aug 2014 | brain injury | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 4 | NCT00549419 Comparator | Oct 2007 → Jan 2009 | — | Klinikum Ludwigshafen | Completed | No outcome recorded |
| Phase 4 | NCT00542516 Comparator | Sep 2006 → Nov 2008 | — | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT06400355 Comparator | Mar → Jun 2024 overdue | — | National Cancer Institute, Egypt | Active not recruiting | No outcome recorded |
| — | NCT05424510 Comparator | Jul 2022 → Feb 2023 | orthostatic hypotension 2 | Mount Sinai Hospital, Canada | Completed | No outcome recorded |
| — | NCT04043598 Comparator | May 2022 → Jul 2027 expected | subarachnoid hemorrhage | Insel Gruppe AG, University Hospital Bern | Recruiting | No outcome recorded |
| — | NCT03048162 Comparator | Feb → May 2017 | — | Tokat Gaziosmanpasa University | Completed | No outcome recorded |
| — | NCT02726620 Background | Jan → Dec 2017 | hypotensive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT02368795 Comparator | Feb 2015 → Jan 2017 | pancreatitis | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT01585740 Comparator | Sep 2011 → Apr 2012 | metabolic acidosis | Makerere University | Completed | No outcome recorded |
| — | NCT01239680 Background | Jan 2011 → Nov 2013 | — | University of Missouri, Kansas City | Completed | No outcome recorded |
| — | NCT01882920 Background | Jun 2010 → Jun 2012 | peritoneal neoplasm | Regina Elena Cancer Institute | Completed | No outcome recorded |
| — | NCT00987701 Comparator | Sep 2009 → May 2011 | — | Nanjing Medical University | Completed | No outcome recorded |
| — | NCT01013090 Comparator | Jul → Dec 2009 | — | Nanjing Medical University | Completed | No outcome recorded |
| — | NCT00973414 Comparator | Mar → Sep 2009 | — | Nanjing Medical University | Completed | No outcome recorded |
| — | NCT00973791 Comparator | Oct 2008 → May 2009 | — | Nanjing Medical University | Completed | No outcome recorded |
| — | NCT00550186 Comparator | Oct → Dec 2007 | hypotensive disorder | Rijnstate Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 34 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ringer's lactate | “hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline” NCT00273728 ↗33“Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 4 ml/kg/h” NCT01882920 ↗ “Ringer's Lactate, solution for infusion will be used as a comparator.” NCT04152096 ↗ “Ringer's Lactate, solution for infusion will be used as a comparator.” NCT03764085 ↗ “Group L (received 500 ml of Ringer's lactate)” NCT03048162 ↗ “compared to Ringer's Lactate (RL).” PMID 39350232 ↗ Oct 2024 |
| Known as | Ringer lactate | “Drug: Ringer lactate” NCT03764085 ↗ |
| Modality | Other / unclassified | “intravenouspreload is administered as cristalloids or colloids” NCT00550186 ↗ |
| Route | Other | “Parenteral solution administered to a maximal dose of 30 ml/kg BW over the first 12 hours post-CABG” NCT00529490 ↗ |